AngioDynamics Q2 revenue +7.6% to $78.3M; adj. loss per share $0.02; guidance cut on margin and EPS

ANGIODYNAMICS INC

2022-Q2 EPS reported -$0.39 revenue$155,251,000

Net sales $78.3M (+7.6% YoY); Med Tech +36.4% driven by atherectomy/thrombectomy.
GAAP net loss $8.4M (-$0.21/share) vs loss $4.3M (-$0.11) a year ago; adjusted loss per share $0.02.
Gross margin 51.8%, down 340 bps due to supply chain, labor shortages, raw material/freight costs.
FY2022 revenue guidance reaffirmed $310-315M; gross margin cut to 52-54% from 55%; adj. EPS guidance to ($0.02)-$0.02.
Full market release of AlphaVac Thrombectomy device commenced after quarter end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.